Evidence map›Paper›PMID 27844282›Full record

ArticleMolecular neurobiology2017

Morphological Changes in a Severe Model of Parkinson's Disease and Its Suitability to Test the Therapeutic Effects of Microencapsulated Neurotrophic Factors.

C Requejo, J A Ruiz-Ortega, H Bengoetxea, A García-Blanco, E Herrán, A Aristieta, M Igartua, J L Pedraz, L Ugedo, R M Hernández and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular neurobiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 2 countries.

C RequejoLaboratory of Clinical and Experimental Neuroscience (LaNCE), Department of Neuroscience, University of the Basque Country UPV/EHU, Leioa, Vizcaya, Spain. catalina.requejo@ehu.eus.ORCID http://orcid.org/0000-0002-5440-5455
J A Ruiz-OrtegaDepartment of Pharmacology, University of the Basque Country (UPV/EHU), Leioa, Vizcaya, Spain.
H BengoetxeaLaboratory of Clinical and Experimental Neuroscience (LaNCE), Department of Neuroscience, University of the Basque Country UPV/EHU, Leioa, Vizcaya, Spain.
A García-BlancoLaboratory of Clinical and Experimental Neuroscience (LaNCE), Department of Neuroscience, University of the Basque Country UPV/EHU, Leioa, Vizcaya, Spain.
E HerránNanoBioCel Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), Vitoria, Alava, Spain.
A AristietaDepartment of Pharmacology, University of the Basque Country (UPV/EHU), Leioa, Vizcaya, Spain.
M IgartuaNanoBioCel Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), Vitoria, Alava, Spain.
J L PedrazNanoBioCel Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), Vitoria, Alava, Spain.
L UgedoDepartment of Pharmacology, University of the Basque Country (UPV/EHU), Leioa, Vizcaya, Spain.
R M HernándezNanoBioCel Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), Vitoria, Alava, Spain.
J V LafuenteLaboratory of Clinical and Experimental Neuroscience (LaNCE), Department of Neuroscience, University of the Basque Country UPV/EHU, Leioa, Vizcaya, Spain.
University of the Basque Country · ES

Funding

Euskal Herriko Unibertsitatea FEDER funds and SGIkerEuskal Herriko Unibertsitatea UFI 11/32Ministerio de Ciencia e Innovación SAF2010-20375The Basque Gobernment GIC 794/13The Basque Gobernment Saiotek SA-2010/00028The Basque Government GIC 794/13
6 · The paper itself

Abstract

The unilateral 6-hydroxydopamine (6-OHDA) lesion of medial forebrain bundle (MFB) in rats affords us to study the advanced stages of Parkinson's disease (PD). Numerous evidences suggest synergic effects when various neurotrophic factors are administered in experimental models of PD. The aim of the present work was to assess the morphological changes along the rostro-caudal axis of caudo-putamen complex and substantia nigra (SN) in the referred model in order to test the suitability of a severe model to evaluate new neurorestorative therapies. Administration of 6-OHDA into MFB in addition to a remarkable depletion of dopamine in the nigrostriatal system induced an increase of glial fibrillary acidic protein (GFAP)-positive cells in SN and an intense immunoreactivity for OX-42, vascular endothelial growth factor (VEGF), and Lycopersycum esculentum agglutinin (LEA) in striatum and SN. Tyrosine hydroxylase (TH) immunostaining revealed a significant decrease of the TH-immunopositive striatal volume in 6-OHDA group from rostral to caudal one. The loss of TH-immunoreactive (TH-ir) neurons and axodendritic network (ADN) was higher in caudal sections. Morphological recovery after the implantation of microspheres loaded with VEGF and glial cell line-derived neurotrophic factor (GDNF) in parkinsonized rats was related to the preservation of the TH-ir cell number and ADN in the caudal region of the SN. In addition, these findings support the neurorestorative role of VEGF+GDNF in the dopaminergic system and the synergistic effect between both factors. On the other hand, a topological distribution of the dopaminergic system was noticeable in the severe model, showing a selective vulnerability to 6-OHDA and recovering after treatment.

Indexed as

Drug CompoundingSeverity of Illness IndexAnimalsFemaleGlial Cell Line-Derived Neurotrophic FactorNeuroprotective AgentsParkinsonian DisordersRatsRats, Sprague-DawleyTreatment OutcomeVascular Endothelial Growth Factor AGlial Cell Line-Derived Neurotrophic FactorNeuroprotective AgentsVascular Endothelial Growth Factor Avascular endothelial growth factor A, rat6-OHDAGDNFNeuroregenerationParkinson’s diseaseRostro-caudal gradientVEGF

Identifiers

PMID27844282
OpenAlexW2553093207

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.